US Stock MarketDetailed Quotes

SLNO Soleno Therapeutics

Watchlist
  • 46.7100
  • +0.4300+0.93%
Close Dec 13 16:00 ET
  • 47.4100
  • +0.7000+1.50%
Post 20:01 ET
2.01BMarket Cap-16.74P/E (TTM)

About Soleno Therapeutics Company

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Company Profile

SymbolSLNO
Company NameSoleno Therapeutics
Listing DateNov 13, 2014
Founded1999
CEODr. Anish Bhatnagar, M.D.
MarketNASDAQ
Employees42
Fiscal Year Ends12-31
Address100 Marine Parkway,Suite 400
CityRedwood City
ProvinceCalifornia
CountryUnited States of America
Zip Code94065
Phone1-650-213-8444
Websitehttp://www.soleno.life

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Anish Bhatnagar, M.D.
  • President, Chief Executive Officer, Chief Operating Officer and Director
  • 4.12M
  • James H. Mackaness
  • Chief Financial Officer and Principal Accounting Officer
  • 1.21M
  • Meredith S. Manning
  • Chief Commercial Officer
  • --
  • Dr. Michael Huang, M.D.
  • Senior Vice President, Clinical Development
  • --
  • Patricia C. Hirano
  • Senior Vice President, Regulatory Affairs
  • 1.03M
  • Kristen Yen
  • Senior Vice President, Clinical Operations
  • --
  • Dawn Carter Bir
  • Director
  • --
  • Dr. Birgitte Volck, M.D.,PhD
  • Independent Director
  • 102.87K
  • Dr. Andrew Sinclair, PhD
  • Independent Director
  • 51.87K
  • Matthew Pauls, J.D.,M.B.A.
  • Lead Independent Director
  • 70.53K
  • William G. Harris
  • Independent Director
  • 111.87K
Heat List
US
Overall
Symbol
Price
% Chg

No Data